Jacobs Levy Equity Management, Inc Alkermes Plc. Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$26.4 - $32.56 $98,683 - $121,709	-3,738 Reduced 0.3%	1,252,300 $33.9 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $4.8 Million - $5.89 Million	-205,208 Reduced 14.04%	1,256,038 $34.8 Million
Q3 2023 Nov 16, 2023	BUY	$27.17 - $31.97 $3.62 Million - $4.26 Million	133,357 Added 10.04%	1,461,246 $40.9 Million
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $751,293 - $891,531	26,510 Added 2.04%	1,327,889 $41.6 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $3.61 Million - $4.13 Million	-142,487 Reduced 9.87%	1,301,379 $36.7 Million
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $3.54 Million - $4.24 Million	-161,539 Reduced 10.06%	1,443,866 $37.7 Million
Q3 2022 Nov 15, 2022	SELL	$22.0 - $31.87 $1.07 Million - $1.55 Million	-48,664 Reduced 2.94%	1,605,405 $35.8 Million
Q2 2022 Aug 15, 2022	SELL	$26.4 - $30.54 $2.56 Million - $2.97 Million	-97,087 Reduced 5.54%	1,654,069 $49.3 Million
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $2.36 Million - $2.86 Million	102,354 Added 6.21%	1,751,156 $46.1 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $1.79 Million - $2.68 Million	-83,476 Reduced 4.82%	1,648,802 $38.4 Million
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $424,422 - $583,512	18,161 Added 1.06%	1,732,278 $53.4 Million
Q2 2021 Aug 16, 2021	BUY	$18.78 - $25.15 $5.65 Million - $7.57 Million	300,918 Added 21.29%	1,714,117 $42 Million
Q1 2021 May 17, 2021	BUY	$18.21 - $23.2 $1.5 Million - $1.92 Million	82,581 Added 6.21%	1,413,199 $26.4 Million
Q4 2020 Feb 16, 2021	SELL	$15.39 - $22.1 $1.06 Million - $1.53 Million	-69,084 Reduced 4.94%	1,330,618 $26.5 Million
Q3 2020 Nov 16, 2020	BUY	$16.16 - $20.66 $3.5 Million - $4.47 Million	216,394 Added 18.29%	1,399,702 $23.2 Million
Q2 2020 Aug 17, 2020	BUY	$13.31 - $19.41 $2.87 Million - $4.19 Million	215,677 Added 22.29%	1,183,308 $23 Million
Q1 2020 May 15, 2020	BUY	$13.06 - $21.24 $629,047 - $1.02 Million	48,166 Added 5.24%	967,631 $14 Million
Q4 2019 Feb 14, 2020	BUY	$17.29 - $21.74 $4.45 Million - $5.59 Million	257,206 Added 38.84%	919,465 $18.8 Million
Q3 2019 Nov 14, 2019	BUY	$19.51 - $24.28 $4.83 Million - $6.02 Million	247,737 Added 59.76%	662,259 $12.9 Million
Q2 2019 Aug 13, 2019	SELL	$21.47 - $37.33 $3.85 Million - $6.69 Million	-179,184 Reduced 30.18%	414,522 $9.34 Million
Q1 2019 May 14, 2019	BUY	$28.4 - $36.49 $4.57 Million - $5.87 Million	160,930 Added 37.19%	593,706 $21.7 Million
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $5.45 Million - $8.7 Million	194,930 Added 81.96%	432,776 $12.8 Million
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $4.03 Million - $4.81 Million	104,281 Added 78.08%	237,846 $10.1 Million
Q2 2018 Aug 14, 2018	BUY	$40.56 - $51.36 $5.27 Million - $6.67 Million	129,955 Added 3599.86%	133,565 $5.5 Million
Q1 2018 May 15, 2018	BUY	$53.61 - $67.26 $193,532 - $242,808	3,610 New	3,610 $209,000
Q4 2017 Feb 13, 2018	SELL	$47.69 - $55.39 $759,701 - $882,362	-15,930 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $508,314 - $563,013	10,340 Added 184.97%	15,930 $810,000
Q2 2017 Nov 09, 2017	BUY	N/A	5,590	5,590 $324,000

Others Institutions Holding ALKS

# of Institutions

361

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

Black Rock Inc. New York, NY

29.1M
Shares

$806 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$526 Million
0.01% of portfolio
Price T Rowe Associates Inc Baltimore, MD

13M
Shares

$360 Million
0.04% of portfolio
Wellington Management Group LLP Boston, MA

12.7M
Shares

$351 Million
0.06% of portfolio
State Street Corp Boston, MA

9.19M
Shares

$254 Million
0.01% of portfolio

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.55B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account